Status:
RECRUITING
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
This prospective, single-center, double-blinded study investigates the biodistribution, dosimetry, safety, and diagnostic ability of Al18F-NOTA-LM3 in patients with well-differentiated neuroendocrine ...
Detailed Description
Somatostatin receptors (SSTR), especially SSTR subtype 2 (SSTR2), are highly expressed in well-differentiated neuroendocrine tumors (NETs). Radiolabeled somatostatin analogs, including 68Ga-DOTATATE, ...
Eligibility Criteria
Inclusion
- Patients aged 18 to 80 years.
- Histologically proven, well-differentiated, NETs (G1 or G2).
- No long-acting somatostatin analog treatment within 4 weeks.
- No PRRT treatment within 8 weeks.
Exclusion
- Combined with other types of tumors.
- Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min).
- Active infection.
- Pregnant or breast-feeding women.
- Inability to perform PET/CT scans.
Key Trial Info
Start Date :
March 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 27 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06056362
Start Date
March 23 2023
End Date
March 27 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, China